Last reviewed · How we verify

Clozaril — Competitive Intelligence Brief

Clozaril (Clozaril) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Neuroscience.

phase 1 Aldehyde oxidase, UDP-glucuronosyltransferase 1-4, 5-hydroxytryptamine receptor 1E Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Clozaril (Clozaril) — Dong Wha Pharmaceutical Co. Ltd..

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Clozaril TARGET Clozaril Dong Wha Pharmaceutical Co. Ltd. phase 1 Aldehyde oxidase, UDP-glucuronosyltransferase 1-4, 5-hydroxytryptamine receptor 1E
Fazaclo Fazaclo Manhattan Psychiatric Center marketed Aldehyde oxidase, UDP-glucuronosyltransferase 1-4, 5-hydroxytryptamine receptor 1E

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Clozaril — Competitive Intelligence Brief. https://druglandscape.com/ci/clozaril. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing